OCT 03, 2019 7:30 AM PDT

Keynote Presentation: CRISPR/Cas9 genome editing in mouse and rat: The PHENOMIN-ICS experience

Presented at: CRISPR 2019
C.E. Credits: P.A.C.E. CE Florida CE
  • Head associate of the Genetic Engineering and Model validation Department Group Leader Genetic Engineering, Institut Clinique de la Souris
      Dr. Marie-Christine Birling received her PhD in Molecular Biology Neurosciences from the University Strasbourg in 1994. She continued her research at the SmithKline Beecham, near London as a postdoctoral fellow trying to better understand the development of glial cells. She then pursued her research in finding new oligodendrocytes specific genes through a post-doctoral fellowship at the University of Edinburgh. She was recruited permanently at the Institut Clinique de la Souris in 2003. Since then she leads the genetic engineering team. In 2008 she was appointed Head associated for the Genetic Engineering and Model Validation Department. She advises scientists on the best approach for generating relevant animal models (mouse and rat). She has initiated more than 1500 à la carte models with some of them leaded to high impact scientific paper. Since 2013, she has implemented the CRISPR/Cas9 technology and now, most of the models are generated through this approach (Knock-Out, conditional Knock-Out, small Knock-In). Marie-Christine is also in charge of internal R&D projects. With her team, she has developed a new CRISPR approach (called CRISMERE) for the generation of structural genomic variants (here Down syndrome models, Birling et al., 2017). She regularly gives courses to Master's students and is invited to give talks


    CRISPR/Cas9 technology has become very popular in the last 5 years and has profoundly changed our way to do genetically engineered animals. I will present the latest development in genome editing at PHENOMIN-ICS.  From  the easy high throughput KO production for the International Mouse Phenotyping consortium  (https://www.mousephenotype.org/) to the generation of complex models, different examples (from simple point mutations to conditional knock-outs) will be shown and discussed.  The benefits of oocyte electroporation, which is much more efficient than microinjection and has allowed to reduce the number of animal needed for all experiments, will be presented. The pertinence of the use of CRISPR base editing (cytidine deaminase) for specific mutations was assessed and the results of our pilot experiment will be shown. And finally, the advantages of the use of embryonic stem cells (with the help of CRISPR) for genetic modifications larger than small knock-ins will be presented.

    Show Resources
    Show Resources
    • See more